What is the Cardiff Oncology Inc. stock price forecast?

Cardiff Oncology Inc. is currently trading at $1.54. View real-time AI analysis on Alpha Lenz.

What is Cardiff Oncology Inc. insider trading activity?

View the latest insider trading data for Cardiff Oncology Inc. on Alpha Lenz.

What is Cardiff Oncology Inc.'s P/E ratio?

Cardiff Oncology Inc.'s P/E ratio is -2.2.

Cardiff Oncology Inc.

NASDAQ · CRDF

$1.54-0.05(-3.14%)Pre-market

Ask about Cardiff Oncology Inc.'s future dividend policy...

Alpha Chat Insight

“Cardiff Oncology Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -71.5%. 3Y revenue CAGR of 15.4% highlights clear growth momentum.”

Ask for details →

Company Overview

Cardiff Oncology Inc. is a biotechnology company focused on the development of precision medicine therapies for cancer treatment. The primary purpose of the organization is to create innovative oncological solutions that target specific genetic profiles of tumors, aiming to improve outcomes for cancer patients. Cardiff Oncology's flagship product, Onvansertib, is an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor currently undergoing clinical trials for various malignancies, including colorectal cancer, castration-resistant prostate cancer, and acute myeloid leukemia. By applying a targeted therapeutic approach, the company seeks to address unmet needs in oncology therapies. Cardiff Oncology plays a significant role in the biotechnology sector by contributing to personalized cancer treatment research, which holds the potential to transform standard care practices. Based in San Diego, California, the company is actively involved in collaborations and research initiatives that explore novel treatment options, reinforcing its commitment to advancing medical science and improving patient quality of life.

CEODr. Mark Erlander Ph.D.

Websitehttps://www.cardiffoncology.com

SectorHealthcare

IndustryBiotechnology

Employees32

Company Statistics

FY 2025

Profile

$102.94MMarket Cap

$593.00KRevenue

0.00Shares Out

32Employees

Margins

N/AGross

-8103.88%EBITDA

-8256.32%Operating

-7732.04%Pre-Tax

-7732.04%Net

Valuation

-2.25P/E

2.27P/B

173.58EV/Sales

-1.80EV/EBITDA

-2.71P/FCF

Growth (CAGR)

15.39%Rev 3Yr

10.13%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-57.65%ROA

-71.45%ROE

-61.56%ROIC

Financial Health

$17.47MCash & Cash Equivalents

$-974.00KNet Debt

36.34%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Cardiff Oncology Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -71.5%. 3Y revenue CAGR of 15.4% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Cardiff Oncology Inc. (ticker: CRDF) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 32 employees. Market cap is $103M.

The current price is $1.54 with a P/E ratio of -2.25x and P/B of 2.27x.

ROE is -71.45% and operating margin is -8256.32%. Annual revenue is $593,000.